Literature DB >> 15583856

The emerging normal and disease-related roles of anaplastic lymphoma kinase.

K Pulford1, L Lamant, E Espinos, Q Jiang, L Xue, F Turturro, G Delsol, S W Morris.   

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, the normal role of which remains to be completely elucidated. Although work carried out in mammals suggests a function in neural development, results from studies in Drosophila indicate an additional role in visceral muscle differentiation. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas, while the occurrence of ALK fusion proteins in anaplastic large cell lymphoma (ALCL) has resulted in the identification of the new tumor entity, ALK-positive ALCL. ALK represents one of few examples of a receptor tyrosine kinase implicated in oncogenesis in both haematopoietic and non-haematopoietic tumors, given that ALK fusions also occur in the mesenchymal tumor known as inflammatory myofibroblastic tumor (IMT). The study of ALK fusion proteins, besides demonstrating their importance in tumor development, has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583856     DOI: 10.1007/s00018-004-4275-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  33 in total

1.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

3.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 4.  High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.

Authors:  Genevieve Conant; Benjamin Fook Lun Lai; Rick Xing Ze Lu; Anastasia Korolj; Erika Yan Wang; Milica Radisic
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 5.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

Review 6.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

7.  Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Authors:  Roberto Piva; Roberto Chiarle; Andrea D Manazza; Riccardo Taulli; William Simmons; Chiara Ambrogio; Valentina D'Escamard; Elisa Pellegrino; Carola Ponzetto; Giorgio Palestro; Giorgio Inghirami
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

8.  ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.

Authors:  Shou-Wei Jia; Sha Fu; Fang Wang; Qiong Shao; Hong-Bing Huang; Jian-Yong Shao
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 9.  The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.

Authors:  Mayumi Higashi; Kohei Sakai; Shigehisa Fumino; Shigeyoshi Aoi; Taizo Furukawa; Tatsuro Tajiri
Journal:  Surg Today       Date:  2019-03-08       Impact factor: 2.549

10.  Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).

Authors:  Emily Greengard; Yael P Mosse; Xiaowei Liu; Charles G Minard; Joel M Reid; Stephan Voss; Keith Wilner; Elizabeth Fox; Frank Balis; Susan M Blaney; Peter C Adamson; Brenda J Weigel
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.